#USA #New York #Securities Fraud #Pomerantz LLP #ADC Therapeutics

Pomerantz Law Firm Investigates ADC Therapeutics

Pomerantz LLP, a leading law firm recognized for its expertise in handling corporate and securities class action litigation, has announced an investigation into ADC Therapeutics SA, a company represented on the NYSE under the ticker ADCT. This investigation aims to protect the interests of shareholders who may have been impacted by the company’s actions or announcements.

The primary focus of the inquiry is whether ADC Therapeutics and its senior leadership have participated in securities fraud or engaged in any unethical business conduct that could adversely affect their investors. The legal team at Pomerantz encourages concerned investors to reach out for further information or to join the ongoing class action lawsuit.

On December 3, 2025, ADC Therapeutics disclosed updated results from their LOTIS-7 Phase 1b open-label clinical trial. This trial evaluated the safety and effectiveness of their drug, ZYNLONTA®, when combined with another novel treatment option, glofitamab (COLUMVI®), for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the initial press release from the company celebrated supportive findings from the trial, it was imperative to note that it also reported that two patients experienced severe adverse events, including one suspected to be treatment-related. Alarmingly, it indicated that cytokine release syndrome manifesting at various severity levels occurred in 36.7% of the participants, raising concerns about the treatment's safety profile.

Upon the release of this study’s findings, the company’s stock witnessed a substantial decline, plunging by $0.65 or approximately 14.13%, resulting in a closure price of $3.95 per share on the same trading day. This drop has sparked considerable concern within the investment community, prompting Pomerantz LLP to take action to investigate whether the company and its executives adequately disclosed the potential risks and adverse effects associated with their treatments.

Pomerantz LLP has established itself as a go-to firm for victims of securities fraud and corporate misconduct over the past 85 years, and its founder, Abraham L. Pomerantz, is often celebrated as a pioneer in the realm of securities class actions. The firm has a track record of securing multimillion-dollar settlements for those affected by unethical practices, thus it seeks to uphold its reputation by assisting those concerned with ADC Therapeutics' recent developments.

If you have invested in ADC Therapeutics and believe your rights have been compromised, it is vital to reach out. You can contact Danielle Peyton at Pomerantz LLP through email or on direct lines to gain specific insights regarding your legal rights and potential participation in the class action.

For more information regarding Pomerantz LLP and their services, visit www.pomlaw.com. Keep in mind that results in past cases do not guarantee similar outcomes in the future. Investing in stocks involves risk, and it’s crucial to remain informed about the companies in which you choose to invest.

Conclusion

With tumultuous events surrounding ADC Therapeutics and the added scrutiny from renowned firms like Pomerantz, it is a crucial time for investors to stay alert and informed about their investments, particularly those with potential securities fraud implications. Investors should consider all facts and take appropriate action to safeguard their investments.